the Creative Commons Attribution 4.0 License
In the SURMOUNT-1 trial published in the New England Journal of Medicine , once-weekly Tirzepatide produced dose-dependent reductions in body weight over 72 weeks in adults with obesity or overweight, with the highest-dose arm showing some of the strongest weight-loss outcomes reported at the time for an incretin-based therapy
The Long-Term Benefits of GLP-1 Medications Beyond Weight Loss Introduction Over the past few years, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the next-generation retatrutide have become household names
Recommended Topics Recommended Topics
PubMed ID: 11713213 Ng FM et al
Anything that squeezes or irritates the carpal tunnel spaces median nerve can cause carpal tunnel syndrome